CN115667246A - 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用 - Google Patents

一种哒嗪类衍生物自由碱的晶型及其制备方法和应用 Download PDF

Info

Publication number
CN115667246A
CN115667246A CN202180035717.8A CN202180035717A CN115667246A CN 115667246 A CN115667246 A CN 115667246A CN 202180035717 A CN202180035717 A CN 202180035717A CN 115667246 A CN115667246 A CN 115667246A
Authority
CN
China
Prior art keywords
degrees
diffraction
diffraction peaks
ray powder
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180035717.8A
Other languages
English (en)
Inventor
杜俊锋
呙临松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN115667246A publication Critical patent/CN115667246A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

涉及一种哒嗪类衍生物自由碱的晶型及其制备方法和应用。具体涉及一种通式(I)所示化合物、其晶型、制备方法和含有治疗有效量的该化合物或其晶型的药物组合物以及其在制备TYK2抑制剂药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (29)

  1. PCT国内申请，权利要求书已公开。
CN202180035717.8A 2020-07-24 2021-07-23 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用 Pending CN115667246A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020107250751 2020-07-24
CN202010725075 2020-07-24
PCT/CN2021/108103 WO2022017494A1 (zh) 2020-07-24 2021-07-23 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN115667246A true CN115667246A (zh) 2023-01-31

Family

ID=79728520

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180035717.8A Pending CN115667246A (zh) 2020-07-24 2021-07-23 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用

Country Status (6)

Country Link
JP (1) JP2023534492A (zh)
KR (1) KR20230043887A (zh)
CN (1) CN115667246A (zh)
CA (1) CA3186000A1 (zh)
TW (1) TW202214603A (zh)
WO (1) WO2022017494A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884454A (zh) * 2012-11-08 2015-09-02 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα应答调节剂的酰胺取代的杂环化合物
CN110475774A (zh) * 2017-03-30 2019-11-19 百时美施贵宝公司 用于制备6-(环丙烷酰氨基)-4-((2-甲氧基-3-(1-甲基-1h-1,2,4-***-3-基)苯基)氨基)-n-(甲基-d3)哒嗪-3-甲酰胺的方法
WO2020156311A1 (zh) * 2019-01-28 2020-08-06 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909140A (zh) * 2019-04-12 2020-11-10 明慧医药（杭州）有限公司 作为tyk2抑制剂的杂环化合物及合成和使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884454A (zh) * 2012-11-08 2015-09-02 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα应答调节剂的酰胺取代的杂环化合物
CN110475774A (zh) * 2017-03-30 2019-11-19 百时美施贵宝公司 用于制备6-(环丙烷酰氨基)-4-((2-甲氧基-3-(1-甲基-1h-1,2,4-***-3-基)苯基)氨基)-n-(甲基-d3)哒嗪-3-甲酰胺的方法
WO2020156311A1 (zh) * 2019-01-28 2020-08-06 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN111757878A (zh) * 2019-01-28 2020-10-09 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用

Also Published As

Publication number Publication date
CA3186000A1 (en) 2022-01-27
WO2022017494A1 (zh) 2022-01-27
KR20230043887A (ko) 2023-03-31
JP2023534492A (ja) 2023-08-09
TW202214603A (zh) 2022-04-16

Similar Documents

Publication Publication Date Title
AU2020202000B2 (en) Bipyrazole derivatives as jak inhibitors
CN115448910A (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
AU2022201061B2 (en) Novel Jak1 selective inhibitors and uses thereof
EP3013835B1 (en) Solid forms of a macrocyclic kinase inhibitor
CN110461847B (zh) (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
AU2017284702B2 (en) Pyrrolopyrimidine crystal for preparing JAK inhibitor
CN113968846A (zh) 一种哒嗪类衍生物的盐、晶型及其制备方法和应用
WO2020035049A1 (zh) 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
CN115667246A (zh) 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
CN111542522B (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
CN112094269B (zh) 一类饱和六元环并杂环类化合物、制备方法和用途
AU2018208516B2 (en) Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof
CN113527299A (zh) 一类含氮稠环类化合物、制备方法和用途
CA3044933A1 (en) Oxoisoquinoline derivatives
EP4103566B1 (en) Fused pyrimidine compounds as kcc2 modulators
CN110577543A (zh) 一种二氢咪唑并吡嗪酮化合物及包含该化合物的组合物及其用途
CN112154144B (zh) 一种1,2,4-三嗪-3-胺类衍生物的晶型及制备方法
CN114591351A (zh) 一种多环化合物及其制备方法和用途
CN115867542A (zh) 新型苯并咪唑化合物
CN114430741A (zh) Egfr抑制剂、组合物及其制备方法
CN111410667A (zh) 新型(1,2,4)***并(1,5-a)吡啶基磷氧化物及其用途
CN112334473B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法
CN111763217B (zh) 一类噻吩并氮杂环类化合物、制备方法和用途
EP4378943A1 (en) 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof
CN117645598A (zh) 氮杂二并多元稠环化合物及其药物组合物和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079587

Country of ref document: HK